ArticleAnalytical and bioanalytical chemistry2025
On the question of correct use of replicates in quantitative label-free proteomics.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Label-free quantitation is the most popular method in proteomics for assessing changes in protein concentrations. However, practical aspects like the optimal use of technical replicates, the impact of removing low-identified protein runs, and the effect of combining information from technical replicates for subsequent differential expression analysis remain debated. This study utilized five LFQ workflows: MaxQuant + Perseus, FragPipe + MSstats, Proteome Discoverer, DirectMS1Quant, and IdentiPy + IQMMA. Previously published data sets acquired for three-species proteomes using Orbitrap FTMS consisted of spikes of Escherichia coli, yeast, and human lysates with known concentration changes that were used for benchmarking the workflows. All tested workflows gave fairly similar results in terms of the number of differentially expressed proteins (DEPs) and quantitative false discovery rate (FDR). Adding more technical replicates either increased the number of DEPs or decreased the FDR, depending on the workflow. Eliminating runs with the lowest number of protein identifications led to an increase in the number of DEPs, but at the cost of elevated FDR, thus reducing the accuracy and precision of protein fold change estimations. The Match-Between-Runs option provides additional DEPs and does not increase empirical FDR in most methods. We found that the selected set of proteomics workflows turned out to be different in answering the practical questions raised above, even for the simple artificial benchmark data set. Our results should serve as a starting point and encourage researchers to more thoroughly test their own approaches in real-world problems.
Indexed as
Identifiers
40628980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.